CRNX (Crinetics Pharmaceuticals) Short-Term Debt to Capital

Corporate company logo of Crinetics Pharmaceuticals (CRNX)

The price history of Crinetics Pharmaceuticals (CRNX) reflects a debt-to-equity ratio of 0.01. Crinetics Pharmaceuticals (CRNX) holds a leading position in developing small molecules for the therapy of rare endocrine system pathologies, positioning the company for potential market monopoly. Substantial cash reserves ensure business resilience until the company achieves positive cash flow. An innovative approach to developing oral tablet forms instead of injections provides the firm with a strategic advantage.

Ratio of Short-Term Indebtedness to Capital: Crinetics Pharma (CRNX) for 07/04/2022 - 09/12/2026

Analytical breakdowns for Crinetics Pharmaceuticals

- stock quotes and analyst forecast:
Stock Price Crinetics Pharma|CRNX - Fair Value Consensus
- business market valuation indicators:
Market Capitalization Crinetics Pharmaceuticals, Inc.|CRNX - Enterprise Value
- book capitalization information:
Net Assets per Single Share Crinetics|CRNX - Accounting Value of Company|Market Value to Book Value Ratio crinetics.com|CRNX - Cumulative Company Assets
- company liabilities and liquidity data:
Total Debt to Capital Crinetics Pharmaceuticals|CRNX - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Crinetics|CRNX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Crinetics Pharmaceuticals, Inc.|CRNX - Company Long-Term Liabilities|Company Short-Term Debts Crinetics|Quick Liquidity Indicator crinetics.com
- company profitability and valuation multiples indicators:
CRNX - Profit After Payment of Taxes
Fundamental valuation:CRNX Crinetics Pharma
Brand item of Crinetics Pharmaceuticals, Inc.

For Crinetics Pharmaceuticals (CRNX), which is scaling the market launch of paltusotine, liquidity control is critical as it prepares for a global commercial rollout. This metric is calculated as the ratio of liabilities maturing within one year to total equity, reflecting the company's reliance on short-term debt financing. Analyzing the short-term debt-to-equity ratio allows for the identification of potential cash flow gaps or, conversely, strategic investment in expansion.

Competitors of Crinetics Pharmaceuticals

Short-Term Debt to Capital ASND|MDGL (Madrigal Corp) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital CORT (Corcept Therapeutics)|Short-Term Debt to Capital rhythmtx.com RYTM|AKRO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital MTSR (Metsera, Inc.)|MoonLake Pharma (MLTX) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio NewAmsterdam Pharma Corp|SLNO (Soleno Therapeutics) - Short-Term Debt to Capital|Short-Term Debt to Capital amicusrx.com|Short-Term Debt to Equity Ratio ETNB (89bio)|AGIO (Agios) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Structure Pharma GPCR|MDXG - Short-Term Debt to Equity Ratio|Rezolute, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital lexpharma.com|MBX (MBX Biosciences) - Short-Term Debt to Equity Ratio|ALT: Short-Term Loans to Capital Ratio|AARD (Aardvark Therapeutics Corp) - Short-Term Debt to Capital|Short-Term Debt to Capital Sagimet Biosciences Inc|Short-Term Debt to Capital BIOA|Short-Term Debt to Equity BMEA (biomeafusion.com)|Short-Term Debt to Equity Quince Therapeutics, Inc. QNCX|Fractyl Health Inc. (GUTS) - Current Liabilities to Capital|VTVT - Short-Term Debt to Equity|ATPC: Short-Term Debt to Equity|PLUR: Short-Term Debt to Capital|SYBX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Lipocine|Matinas BioPharma Holdings Inc. (MTNB) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Spruce Biosciences (SPRB)|Short-Term Debt to Equity Ratio Galecto Corporation GLTO|Short-Term Debt to Capital CTCX (Carmell Corporation)|LUMO - Short-Term Debt to Equity Ratio|ONVO - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital RDUS (Radius Recycling Inc.)